Insight Molecular Diagnostics (IMDX) Capital Expenditures (2015 - 2026)

Insight Molecular Diagnostics has disclosed Capital Expenditures across 12 years of filings, most recently posting $613000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $613000.0, up 99.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (up 336.92% YoY), and the FY2025 annual result was $3.2 million, up 517.25% from the prior year.
• Capital Expenditures came in at $613000.0 for Q1 2026 at Insight Molecular Diagnostics, down from $1.5 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q1 2022 to a low of -$564000.0 in Q3 2023.
• The 5-year median for Capital Expenditures is $349000.0 (2025), against an average of $556933.3.
• Across the five-year window, Capital Expenditures sank 165.66% in 2023 and surged 1179.17% in 2025, its largest moves.
• Insight Molecular Diagnostics' Capital Expenditures stood at $802000.0 in 2022, then sank by 67.08% to $264000.0 in 2023, then dropped by 18.94% to $214000.0 in 2024, then surged by 591.12% to $1.5 million in 2025, then sank by 58.55% to $613000.0 in 2026.
• The last three Capital Expenditures figures came in at $613000.0 (Q1 2026), $1.5 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.